Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6708207 | 0.99 | MTNR1A (0.46) | MTNR1AMTNR1BBRD4ROCK2ARHGDIA | |
| SCHEMBL6545449 | 0.98 | MTNR1A (0.46) | MTNR1AMTNR1BBRD4ROCK2ARHGDIA | |
| SCHEMBL5833927 | 0.81 | ROCK2 (0.43) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833283 | 0.78 | GBA1 (0.46) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL6545036 | 0.78 | ROCK2 (0.43) | ROCK2ARHGDIAROCK1MAPTALDH1A1 | |
| SCHEMBL5832943 | 0.78 | ALPL (0.54) | ACHE | |
| SCHEMBL5833530 | 0.77 | MAPK1 (0.44) | ALDH1A1 | |
| SCHEMBL6707469 | 0.77 | DRD2 (0.47) | ROCK2ARHGDIAROCK1MAPT | |
| Hydrochloric Acid SCHEMBL6709626 | 0.77 | ROCK2 (0.43) | ROCK2ARHGDIAROCK1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL6709625 | 0.76 | DRD2 (0.46) | ROCK2ARHGDIAROCK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | claimed |
| EP-1379502-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | claimed |
| WO-2002083640-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | claimed |
| EP-1317430-B1 | (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| EP-1379502-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083640-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | CHRNA1, CHRNA2, CHRNA10 | MTNR1A 131/4885MTNR1B 252/4885BRD4 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.